乙型肝炎病毒基因类型与干扰素治疗效果关系

The relationship between HBV genotypes and anti-virus therapeutic efficacy of interferon

目的观察干扰素治疗B、C基因型慢性乙型肝炎患者的临床疗效。方法20例B基因型慢性乙型肝炎患者（B组）及23例C基因型慢性乙型肝炎患者（C组）均给予干扰素α-1b500万u，肌内注射，隔日一次，疗程1年，观察两组患者血清病毒学指标、肝功能变化及药物不良反应等情况。结果治疗后B组、C组在HBV-DNA阴转率（60．0％、39．1％）、HBeAg阴转率（42．9％、30．8％）、抗HBe阳转率（35．7％、23．1％）、ALT复常率（85．0％、73．9％）等方面比较，差异均无统计学差异（t=1．86、0．69、0．68、0．79，均P〉0．05）。结论干扰素α-1b抗病毒疗效在B、C基因型间无明显差异。

Objective To study the effects of Interferon（IFN） in chronic hepatitis B patients genotype B and C. Methods 20 eases were genotype B,23 cases were genotype C, all the patients were treated with 5 million units of IFN-α-1b,im ,qod,for 12 months, viral markers, liver function and adverse drug reactions were observed. Results There was no statistically significant difference between B, C genotype in the negative conversion rate of HBV-DNA （60.0% ,39. 1% ） ,the negative conversion rate of HBeAg（42.9% 、30. 8% ）, anti-HBe seroeonversion rate（ 35.7% 23. 1% ） and the rate ALT normalization（ 85.0% ,73.9% ） （ t = 1.86,0. 69 、0. 68 、0. 79, P 〉 0. 05 ）. Conclusion The results suggested that therapeutic efficacy of IFN-α-1 b was not signifiqandy different between B ,C genotypes.